Table 1.
Patient Demographics and Baseline Characteristics
| SC-LA Formulated With a Biodegradable, Dual Polymer-based, Extended-release Delivery System Dose Groups | ||||
|---|---|---|---|---|
| 1 Month, 7.5 mg (n5120) | 3 Month, 22.5 mg (n5117) | 4 Month, 30 mg (n590) | 6 Month, 45 mg (n5111) | |
| Mean age (range) | 72.8 (52-85) | 73.1 (46-85) | 73.5 (53-84) | 73.2 (50-86) |
| Age, years, n (%) | ||||
| 40-49 | 0 | 1 (0.9) | 0 | 0 |
| 50-59 | 8 (6.7) | 6 (5.1) | 6 (6.7) | 6 (5.4) |
| 60-69 | 28 (23.3) | 27 (23.1) | 20 (22.2) | 25 (22.5) |
| 70-79 | 60 (50.0) | 52 (44.4) | 42 (46.7) | 55 (49.6) |
| 80-89 | 24 (20.0) | 31 (26.5) | 22 (24.4) | 25 (22.5) |
| Height, in, mean (range) | 69.0 (62-75) | 68.2 (55-74) | 69.0 (60-78) | 68.9 (62-76) |
| Weight, lbs, mean (range) | 185.3 (126-287) | 186.1 (130-296) | 196.5 (133-313) | 190.1 (109-321) |
| Race, n (%) | ||||
| White | 92 (76.7) | 93 (79.5) | 71 (78.9) | 84 (75.7) |
| Black | 15 (12.5) | 13 (11.1) | 10 (11.1) | 19 (17.1) |
| Hispanic | 13 (10.8) | 7 (6.0) | 8 (8.9) | 6 (5.4) |
| Asian | 0 | 3 (2.6) | 0 | 1 (0.9) |
| Other | 0 | 1 (0.9) | 1 (1.1) | 1 (0.9) |
SC-LA, subcutaneously administered leuprolide acetate.